Buenos Aires - Delayed Quote • ARS Gilead Sciences, Inc. (GILD.BA) Follow Add holdings 27,900.00 -425.00 (-1.50%) At close: May 9 at 4:56:27 PM GMT-3 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for GILD.BA 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: GILD.BA View More All News Press Releases SEC Filings 2 High-Yield Dividend Stocks to Buy in May and Hold Forever Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton 3 Value Stocks with Mounting Challenges Gilead reports final outcomes from trial of bulevirtide for chronic HDV How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock Gilead to Invest $11 Billion to Bolster Domestic Operations Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing Gilead boosts planned US investments by $11 billion amid tariff threat Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025 Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025